Some of the most common peptides for weight loss are glucagon-like peptide 1 (GLP-1) receptor agonists. They include semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound).

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

NAD+ IonToPatch – Utilizing iontophoresis, a non-invasive transdermal drug delivery system that uses a voltage gradient to increase skin permeability, allowing for effective NAD+ absorption. The latex ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

Is Compounded Semaglutide Effective for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Is compounded semaglutide effective for weight loss? Here’s the short ...

What Is the Maximum Semaglutide Dose for Weight Loss? The maximum semaglutide dose for weight loss is 2.4 milligrams (mg) per week. Your healthcare provider will start you on a lower weekly dose ...

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...

The trend of using peptides as drug molecules has picked up momentum in the recent times owing to development in their synthesis and modification technologies, in combination with the improvement of ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

New obesity definition sidelines BMI to focus on health Drug makers are building on the success of medications such as Ozempic and Wegovy, which contain the active ingredient semaglutide ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...